Digital therapeutics company providing easy-to-use cardiac scale for monitoring cardiorenal conditions. The scale detects signals through a person's feet and sends data to the clinical care team. Bodyport has received FDA clearance for its cardiac scale and aims to provide optimized interventions tailored to the patient. The company was founded in 2014 and headquartered in Mountain View, United States. It has raised $15.8M in series a funding, with backing from Boehringer Ingelheim Venture Fund, Initialized Capital, Playground Global, Y Combinator, and others. The company operates in the Life Sciences - Cardiac and Vascular Disorders, HealthTech - Disease Self Management, High Tech - IoT Applications space. Its offerings span Wearable Technology - Health and Wellness Devices - Cardiac and Healthcare IT - Value Based Care - Remote.
Bodyport
Series ADigital therapeutics company providing easy-to-use cardiac scale for monitoring cardiorenal conditions. The scale detects signals through a person's feet and sends data to the clinical care team. Bodyport has received FDA clearance for its cardiac scale and aims to provide optimized interventions tailored to the patient. The company was founded in 2014 and headquartered in Mountain View, United States. It has raised…
About
Business model
Wearable Technology > Health and Wellness Devices > Cardiac,
Disease Self Management > Cardiac and Vascular Disorders > Monitoring > Heart Health > Device,
Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Cardiology,
Cardiac and Vascular Disorders > Medical Devices > Monitoring Devices > Cardiac Health,
Y Combinator Batches > 2015 > Summer
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.